深度学习组织病理图像预测乳腺癌复发风险与化疗获益
这项多中心模型开发与验证研究基于常规组织病理全切片图像和临床特征构建多模态深度学习模型,用于预测激素受体阳性、HER2阴性早期乳腺癌的Oncotype DX 21基因复发评分。模型在TAILORx试验中验证,并在六个外部队列中展现良好泛化性,可指导化疗决策并减少不必要的化疗。
要点
- AI风险分层对无复发生存间隔等预后终点具有预后价值。
- 绝经前AI高风险患者可见化疗获益,绝经后AI低风险患者未见化疗获益。
核心结论
- AI应用于常规组织病理可作为指导激素受体阳性、HER2阴性早期乳腺癌化疗决策的实用且可扩展工具,有望减少不必要化疗并拓宽精准肿瘤学可及性。
研究设计与样本
- 模型在TAILORx随机试验中微调和验证(质控后8284例患者),并在六个独立外部队列中验证。
临床怎么用
- 可将AI模型用于常规病理切片以估计Oncotype DX复发评分,辅助激素受体阳性、HER2阴性早期乳腺癌的化疗决策。
- AI风险分层可识别可能从化疗获益的绝经前高风险患者,以及可能避免化疗的绝经后低风险患者。
- 在基因组检测不可及或不可负担的资源有限环境中,AI方法可作为一种可扩展的替代工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic assays such as Oncotype DX have transformed adjuvant treatment selection for hormone receptor-positive, HER2-negative, early breast cancer but remain inaccessible to many patients because of high cost and logistical barriers. We aimed to develop and validate an artificial intelligence (AI) model that estimates Oncotype DX 21-gene recurrence scores directly from routine histopathology slides and clinicopathological variables. METHODS: In this multicentre, model development and validation study, a multimodal deep-learning model was trained on digital whole-slide images and clinical features using a foundation model pre-trained on 171 189 histopathology slides for predicting Oncotype DX recurrence score. We included slides from patients with hormone receptor-positive, HER2-negative, invasive breast cancers and without scanning artifacts and with at least 100 tissue tiles (1·6 mm2). The model was fine-tuned and validated on the TAILORx randomised trial (8284 patients after quality control). Prognostic and predictive performance was assessed in the TAILORx-test set and externally validated in six independent cohorts (Carmel, Haemek, and Sheba medical centres [Israel], the University of Chicago Medical Center [USA], the Australian Breast Cancer Tissue Bank [Australia], and the Cancer Genome Atlas Breast Invasive Carcinoma project [USA]). FINDINGS: In the TAILORx-test set (n=2407), the AI model classified 1097 (45·6%) patients as low risk, 1021 (42·4%) as intermediate risk, and 289 (12·0%) as high risk. For identifying high genomic-risk disease (recurrence score ≥26), the area under the curve (AUC) was 0·898 (95% CI 0·879-0·913). AI-based risk stratification was prognostic for recurrence-free interval (hazard ratio 2·61 [95% CI 1·68-4·04]), distant recurrence-free interval (2·88 [1·73-4·79]), and disease-free survival (1·32 [0·92-1·89]). Chemotherapy benefit was evident in premenopausal patients classified by AI as being at high risk (0·63 [0·46-0·86]) but absent in postmenopausal patients classified by AI as being at low risk (0·94 [0·78-1·12]). 151 (31·3%) clinically high-risk postmenopausal women (by MINDACT criteria) were reclassified as low AI risk with no chemotherapy benefit. Analysis on external cohorts (5497 patients) showed that the model is transferable to new data with high generalisability (recurrence score ≥26 AUC ranging from 0·858 to 0·903). INTERPRETATION: These findings show that AI applied to routine histopathology can serve as a practical and scalable tool for guiding chemotherapy decisions in hormone receptor-positive, HER2-negative, early breast cancer. This approach has the potential to reduce unnecessary chemotherapy and broaden access to precision oncology, particularly in resource-limited settings where genomic testing remains unavailable or unaffordable. FUNDING: Israel Innovation Authority (Kamin), Zimin Institute for Artificial Intelligence Solutions in Healthcare, Israel Precision Medicine Partnership program, and Israel Cancer Research Fund.
引用
- Shamai G, Cohen S, Binenbaum Y, et al. Deep learning on histopathological images to predict breast cancer recurrence risk and chemotherapy benefit: a multicentre, model development and validation study. Lancet Oncol. 2026. PMID: 41831466. doi:10.1016/S1470-2045(25)00727-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。